Merck Expands Singapore Lab for Asia Pacific Biosafety Testing

Merck has expanded its Singapore lab to offer advanced biosafety testing services for biopharma customers in Asia Pacific.

The expansion adds the first BioReliance^® Cell Line Characterization and GMP Next-Generation Sequencing capabilities in the region, enabling faster biologics development with improved sensitivity and a shift towards animal-free testing.

Merck's Singapore laboratory will become the first BioReliance facility in Asia-Pacific to offer both Cell Line Characterization services and GMP NGS capabilities, as well as advanced molecular methods including Blazar^®, a proprietary platform for rapid virus detection.

The expansion supports the industry's move towards state-of-the-art quality control testing of biologics and 3Rs (Replacement, Reduction, and Refinement of animal use) through advanced molecular methods.